BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 7, 2024
See today's BioWorld
Home
» Somaxon Secures Partner P&G to Co-Promote Insomnia Drug
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Somaxon Secures Partner P&G to Co-Promote Insomnia Drug
Aug. 26, 2010
By
Catherine Hollingsworth
No Comments
San Diego-based Somaxon Pharmaceuticals Inc. plans to launch its Silenor insomnia drug in September with the help of Proctor & Gamble Co., which will co-promote the prescription drug in the U.S. (BioWorld Today)
BioWorld